C1 inhibitor in canine intravascular hemolysis (C1INCH): study protocol for a randomized controlled trial.

ABSTRACT: BACKGROUND:Immune-mediated hemolytic anemia (IMHA) is a common disease that affects all breeds of dogs and is associated with significant morbidity and mortality. Intravascular hemolysis of erythrocytes in IMHA is caused by complement activation and is often fatal. No current treatments target complement activation in canine IMHA. Human C1 esterase (C1-INH) reduces canine complement-mediated hemolysis in vitro, and a recent pharmacokinetic analysis of an FDA licensed formulation of C1-INH in dogs confirmed that a 50 IU/kg dose of C1-INH is safe to administer to dogs, and effectively inhibits canine complement mediated hemolysis ex-vivo. The C1INCH randomized controlled trial will evaluate the efficacy of this drug in dogs with intravascular hemolysis. METHODS:We will conduct a multicenter,

SUBMITTER: Goggs R 

PROVIDER: S-EPMC6937664 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature